2101505-58-0

Cefazolin-¹³C₂,¹⁵N is intended for use as an internal standard for the quantification of cefazolin by GC- or LC-MS. Cefazolin is a broad-spectrum cephalosporin antibiotic that is active in vitro against various Gram-positive and Gram-negative bacteria (MICs = 0.2-12.5 μg/ml). It also inhibits the growth of clinical isolates of S. aureus, E. coli, P. mirabilis, and K. pneumoniae (MICs = 0.1-25 μg/ml). In vivo, cefazolin protects against S. aureus, E. coli, and P. mirabilis infection in mice (ED₅₀s = <0.09-1.78, 0.44-3.63, and 2.31-5.2 mg/animal, respectively). Formulations containing cefazolin have been used to treat a variety of bacterial infections.

Cefazolin-13C2,15N (Cephazolin-13C2,15N) is 13C and 15N labeled Cefazolin. Cefazolin (Cephazolin) is a first-generation cephalosporin antibiotic and can be used in varieties of bacterial infections research[1]. Cefazolin has anti-inflammatory effect and can attenuate post-operative cognitive dysfunction (POCD)[2].

Store at -20°C

[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. DOI:10.1177/1060028018797110
[2] R Quintiliani, et al. Cefazolin. Ann Intern Med. 1978 Nov;89(5 Pt 1):650-6. DOI:10.7326/0003-4819-89-5-650
[3] Peng Liang, et al. Perioperative use of cefazolin ameliorates postoperative cognitive dysfunction but induces gut inflammation in mice. J Neuroinflammation. 2018 Aug 22;15(1):235. DOI:10.1186/s12974-018-1274-6
[4] Barbara ?y?yńska-Granica, et al. The anti-inflammatory potential of cefazolin as common gamma chain cytokine inhibitor. Sci Rep. 2020 Feb 19;10(1):2886. DOI:10.1038/s41598-020-59798-3